Phaseline

Companies › Cogent Biosciences

Cogent Biosciences: clinical trials, targets and expected readouts

5 active drug programs in 6 registered trials: 3 Phase 1, 2 Phase 2, 1 Phase 3; Oncology, Hematology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CGT9486
FIP1L1-PDGFRα inhibitor
PDGFRAPhase 3Advanced Gastrointestinal Stromal TumorsJan 2030
bezuclastinib
KIT inhibitor
KITPhase 2Advanced Systemic Mastocytosis (AdvSM); SSMJul 2027
CGT4859
selective FGFR2/3 inhibitor
FGFR2, FGFR3Phase 1Intrahepatic Cholangiocarcinoma (Icc)Mar 2027
CGT4255
Selective ERBB2 inhibitor
ERBB2Phase 1Advanced Solid Tumor, AdultMay 2028
CGT6297
PIK3CA mutant-selective inhibitor
PIK3CAPhase 1PIK3CA MutationsJul 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06777316CGT4859Phase 1Intrahepatic Cholangiocarcinoma (Icc)OncologyMar 2027
NCT04996875bezuclastinibPhase 2Advanced Systemic Mastocytosis (AdvSM)OncologyJul 2027
NCT07361562CGT4255Phase 1Advanced Solid Tumor, AdultOncologyMay 2028
NCT07383506CGT6297Phase 1PIK3CA MutationsOncologyJul 2029
NCT05186753bezuclastinibPhase 2SSMHematologyJan 2030
NCT05208047CGT9486Phase 3Advanced Gastrointestinal Stromal TumorsOncologyJan 2030

From the company's SEC filings

Cash and short-term investments of $791m on 2026-09-30; operating cash outflow about $329m a year; runway about 29 months at that burn, to Feb 2029; 1 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 18 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ERBB2 (1) FGFR2 (1) FGFR3 (1) PIK3CA (1) KIT (1) PDGFRA (1)

Companies with the same targets

Beijing Biotech Roche Eli Lilly AstraZeneca Jiangsu HengRui Medicine Tyra Biosciences Daiichi Sankyo Chia Tai Tianqing Pharmaceutical Group Exelixis Deciphera Pharmaceuticals

Companies built like this

ORIC Pharmaceuticals Immunome ArriVent BioPharma Olema Pharmaceuticals Blueprint Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.